Cross-reactivity towards SARS-CoV-2: the potential role of low-pathogenic human coronaviruses.
作者信息
Ma Zhongren, Li Pengfei, Ji Yuepeng, Ikram Aqsa, Pan Qiuwei
机构信息
Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, China.
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam 3015 CN, Netherlands.
出版信息
Lancet Microbe. 2020 Aug;1(4):e151. doi: 10.1016/S2666-5247(20)30098-7. Epub 2020 Aug 6.
Abstract
摘要
相似文献
1
Cross-reactivity towards SARS-CoV-2: the potential role of low-pathogenic human coronaviruses.
Lancet Microbe. 2020 Aug;1(4):e151. doi: 10.1016/S2666-5247(20)30098-7. Epub 2020 Aug 6.
2
Evidence for increased SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal coronaviruses.
Cell Rep. 2021 Dec 28;37(13):110169. doi: 10.1016/j.celrep.2021.110169. Epub 2021 Dec 7.
3
High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa.
Int J Infect Dis. 2021 Jan;102:577-583. doi: 10.1016/j.ijid.2020.10.104. Epub 2020 Nov 8.
4
A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2.
JCI Insight. 2021 Apr 22;6(8):146316. doi: 10.1172/jci.insight.146316.
5
Epitope profiling reveals binding signatures of SARS-CoV-2 immune response in natural infection and cross-reactivity with endemic human CoVs.
Cell Rep. 2021 May 25;35(8):109164. doi: 10.1016/j.celrep.2021.109164. Epub 2021 May 6.
6
Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications.
Front Immunol. 2021 Feb 17;12:627285. doi: 10.3389/fimmu.2021.627285. eCollection 2021.
7
Cross-Recognition of SARS-CoV-2 B-Cell Epitopes with Other Betacoronavirus Nucleoproteins.
Int J Mol Sci. 2022 Mar 10;23(6):2977. doi: 10.3390/ijms23062977.
8
The Emergence of Human Pathogenic Coronaviruses: Lectins as Antivirals for SARS-CoV-2.
Curr Pharm Des. 2020;26(41):5286-5292. doi: 10.2174/1381612826666200821120409.
9
Incomplete IgG avidity maturation after seasonal coronavirus infections.
J Med Virol. 2022 Jan;94(1):186-196. doi: 10.1002/jmv.27291. Epub 2021 Aug 27.
10
Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity.
Nat Commun. 2021 Feb 19;12(1):1152. doi: 10.1038/s41467-021-20973-3.
引用本文的文献
1
Viral Epitope Scanning Reveals Correlation between Seasonal HCoVs and SARS-CoV-2 Antibody Responses among Cancer and Non-Cancer Patients.
Viruses. 2024 Mar 13;16(3):448. doi: 10.3390/v16030448.
2
SARS-CoV and SARS-CoV -2 cross-reactive antibodies in domestic animals and wildlife in Nigeria suggest circulation of sarbecoviruses.
One Health. 2024 Mar 12;18:100709. doi: 10.1016/j.onehlt.2024.100709. eCollection 2024 Jun.
3
Antibody-Dependent Enhancement with a Focus on SARS-CoV-2 and Anti-Glycan Antibodies.
Viruses. 2023 Jul 20;15(7):1584. doi: 10.3390/v15071584.
4
Respiratory infections in children and adolescents in Germany during the COVID-19 pandemic.
J Health Monit. 2023 Jun 14;8(2):20-38. doi: 10.25646/11437. eCollection 2023 Jun.
5
Assessment of Broadly Reactive Responses in Patients With MERS-CoV Infection and SARS-CoV-2 Vaccination.
JAMA Netw Open. 2023 Jun 1;6(6):e2319222. doi: 10.1001/jamanetworkopen.2023.19222.
6
Unravelling Antigenic Cross-Reactions toward the World of Coronaviruses: Extent of the Stability of Shared Epitopes and SARS-CoV-2 Anti-Spike Cross-Neutralizing Antibodies.
Pathogens. 2023 May 13;12(5):713. doi: 10.3390/pathogens12050713.
7
Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses.
Antiviral Res. 2023 Mar;211:105555. doi: 10.1016/j.antiviral.2023.105555. Epub 2023 Feb 14.
8
Fourth Dose of mRNA COVID-19 Vaccine Transiently Reactivates Spike-Specific Immunological Memory in People Living with HIV (PLWH).
Biomedicines. 2022 Dec 15;10(12):3261. doi: 10.3390/biomedicines10123261.
9
The clinical and virological features of two children's coinfections with human adenovirus type 7 and human coronavirus-229E virus.
Front Public Health. 2022 Nov 15;10:1048108. doi: 10.3389/fpubh.2022.1048108. eCollection 2022.
10
Pre-existing humoral immunity to low pathogenic human coronaviruses exhibits limited cross-reactive antibodies response against SARS-CoV-2 in children.
Front Immunol. 2022 Oct 19;13:1042406. doi: 10.3389/fimmu.2022.1042406. eCollection 2022.
本文引用的文献
1
Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study.
Lancet Microbe. 2020 Jul;1(3):e111-e118. doi: 10.1016/S2666-5247(20)30053-7. Epub 2020 Jun 3.
2
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.
Cell. 2020 Jun 25;181(7):1489-1501.e15. doi: 10.1016/j.cell.2020.05.015. Epub 2020 May 20.
3
Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19.
J Infect. 2020 Aug;81(2):318-356. doi: 10.1016/j.jinf.2020.03.044. Epub 2020 Apr 10.
4
Potential association between COVID-19 mortality and health-care resource availability.
Lancet Glob Health. 2020 Apr;8(4):e480. doi: 10.1016/S2214-109X(20)30068-1. Epub 2020 Feb 25.
5
Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.
Lancet. 2016 Oct 8;388(10053):1545-1602. doi: 10.1016/S0140-6736(16)31678-6.
Zotero 插件